

Supplementary Table 4. Stratified analysis: risk of study outcomes among individuals with available baseline eGFR, overall and stratified by baseline CKD status.

		Exposure	All individuals (with recorded eGFR)*					CKD (with recorded eGFR)*					No CKD (with recorded eGFR)*				
			N	Cases	IR per 1000 person-years	HR	95% CI	N	Cases	IR per 1000 person-years	HR	95% CI	N	Cases	IR per 1000 person-years	HR	95% CI
Mortality	ITT	Non-initiator	40,978	1680	19.53	1.0		7048	607	41.26	1.0		33,930	1073	15.05	1.0	
		SGLT2i initiator	12,676	304	10.28	0.56	(0.49–0.64)	1170	58	21.06	0.54	(0.40–0.72)	11,506	246	9.17	0.56	(0.48–0.65)
	OT	Non-initiator	40,978	1620	20.84	1.0		7048	597	42.32	1.0		33,930	1023	16.07	1.0	
		SGLT2i initiator	12,676	102	6.14	0.35	(0.28–0.43)	1170	20	15.07	0.42	(0.27–0.67)	11,506	82	5.37	0.33	(0.26–0.42)
	AT	Non-use	43,639	1696	20.72	1.0		7446	613	41.60	1.0		36,193	1083	16.13	1.0	
		Current use of SGLT2i	17,832	173	6.02	0.36	(0.30–0.42)	1531	30	14.18	0.43	(0.29–0.63)	16,301	143	5.37	0.34	(0.28–0.41)
		Recent use of SGLT2i	9432	30	19.69	1.11	(0.77–1.60)	943	2	12.66	0.31	(0.08–1.27)	8489	28	20.50	1.32	(0.90–1.93)
Past use of SGLT2i		5838	85	24.74	1.22	(0.97–1.52)	721	20	44.04	1.12	(0.71–1.78)	5117	65	21.80	1.21	(0.94–1.57)	
Severe renal disease	ITT	Non-initiator	40,555	1047	12.50	1.0		6625	760	59.46	1.0		33,930	287	4.04	1.0	
		SGLT2i initiator	12,655	138	4.70	0.57	(0.47–0.69)	1149	61	23.23	0.53	(0.40–0.69)	11,506	77	2.88	0.63	(0.48–0.82)
	OT	Non-initiator	40,555	1021	13.51	1		6625	748	61.22	1.0		33,930	273	4.31	1.0	
		SGLT2i initiator	12,655	43	2.60	0.37	(0.27–0.51)	1149	21	16.16	0.44	(0.28–0.70)	11,506	22	1.44	0.30	(0.19–0.48)
	AT	Non-use	43,165	1074	13.50	1.0		6994	773	60.53	1.0		36,171	301	4.51	1.0	
		Current use of SGLT2i	17,791	70	2.44	0.33	(0.26–0.43)	1494	30	14.54	0.38	(0.26–0.55)	16,297	40	1.50	0.31	(0.22–0.44)
		Recent use of SGLT2i	9369	9	5.96	0.68	(0.35–1.31)	901	2	13.32	0.28	(0.07–1.14)	8468	7	5.14	1.16	(0.55–2.48)
Past use of SGLT2i		5776	32	9.46	0.83	(0.58–1.19)	682	16	37.83	0.73	(0.44–1.21)	5094	16	5.41	0.97	(0.58–1.63)	
CV	ITT	Non-initiator	36,716	450	5.90	1.0		5883	136	11.27	1.0		30,833	314	4.89	1.0	
		SGLT2i initiator	11,529	125	4.70	0.75	(0.61–0.94)	979	26	11.66	1.08	(0.67–1.73)	10,550	99	4.07	0.70	(0.55–0.89)
	OT	Non-initiator	36,716	412	5.99	1.0		5883	131	11.34	1.0		30,833	281	4.91	1.0	
		SGLT2i initiator	11,529	48	3.20	0.55	(0.40–0.76)	979	9	8.13	0.80	(0.38–1.67)	10,550	39	2.81	0.50	(0.35–0.72)

		Exposure	All individuals (with recorded eGFR)*					CKD (with recorded eGFR)*					No CKD (with recorded eGFR)*				
			N	Cases	IR per 1000 person-years	HR	95% CI	N	Cases	IR per 1000 person-years	HR	95% CI	N	Cases	IR per 1000 person-years	HR	95% CI
	AT	Non-use	39,081	427	5.90	1.0		6196	132	10.95	1.0		32,885	295	4.89	1.0	
		Current use of SGLT2i	16,228	112	4.31	0.77	(0.61–0.96)	1286	20	11.48	1.19	(0.71–2.01)	14,942	92	3.80	0.71	(0.55–0.91)
		Recent use of SGLT2i	8520	13	9.48	1.56	(0.89–2.73)	774	2	15.69	1.34	(0.32–5.60)	7746	11	8.84	1.63	(0.89–3.00)
		Past use of SGLT2i	5248	23	7.47	1.16	(0.76–1.79)	580	8	21.99	2.08	(0.98–4.40)	4668	15	5.53	0.95	(0.56–1.61)
MI	ITT	Non-initiator	36,716	230	3.02	1.0		5883	64	5.31	1.0		30,833	166	2.59	1.0	
		SGLT2i initiator	11,529	82	3.09	0.99	(0.75–1.30)	979	18	8.08	1.38	(0.75–2.54)	10,550	64	2.63	0.90	(0.66–1.24)
	OT	Non-initiator	36,716	211	3.07	1.0		5883	61	5.28	1.0		30,833	150	2.62	1.0	
		SGLT2i initiator	11,529	31	2.07	0.68	(0.45–1.01)	979	7	6.32	1.33	(0.54–3.24)	10,550	24	1.73	0.59	(0.37–0.94)
	AT	Non-use	39,081	220	3.04	1.0		6196	62	5.14	1.0		32,885	158	2.62	1.0	
		Current use of SGLT2i	16,228	72	2.77	0.93	(0.70–1.24)	1286	16	9.18	1.82	(0.96–3.43)	14,942	56	2.31	0.81	(0.58–1.12)
		Recent use of SGLT2i	8520	9	6.56	2.00	(1.01–3.94)	774	1	7.84	1.28	(0.17–9.64)	7746	8	6.43	2.17	(1.05–4.46)
		Past use of SGLT2i	5248	11	3.57	1.06	(0.57–1.97)	580	3	8.24	1.39	(0.42–4.64)	4668	8	2.95	0.97	(0.47–2.00)
IS	ITT	Non-initiator	36,716	194	2.54	1.0		5883	56	4.64	1.0		30,833	138	2.15	1.0	
		SGLT2i initiator	11,529	38	1.43	0.51	(0.35–0.73)	979	7	3.14	0.58	(0.23–1.45)	10,550	31	1.27	0.48	(0.31–0.72)
	OT	Non-initiator	36,716	176	2.56	1.0		5883	54	4.67	1.0		30,833	122	2.13	1.0	
		SGLT2i initiator	11,529	14	0.93	0.38	(0.21–0.67)	979	1	0.90	0.13	(0.02–1.13)	10,550	13	0.94	0.39	(0.21–0.71)
	AT	Non-use	39081	182	2.51	1.0		6196	54	4.48	1.0		32,885	128	2.12	1.0	
		Current use of SGLT2i	16,228	37	1.42	0.59	(0.41–0.86)	1286	3	1.72	0.35	(0.10–1.24)	14,942	34	1.40	0.62	(0.42–0.93)
		Recent use of SGLT2i	8520	3	2.19	0.87	(0.27–2.73)	774	1	7.84	1.87	(0.24–14.55)	7746	2	1.61	0.69	(0.17–2.81)
		Past use of SGLT2i	5248	10	3.25	1.16	(0.61–2.23)	580	5	13.74	3.61	(1.32–9.86)	4668	5	1.84	0.71	(0.28–1.75)

Reference group=non-initiator/non-use. *Adjusted estimates obtained using a Cox proportional hazard regression model including all variables in **Supplementary table 1**.

AT, As-treated; CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio; IR, incidence rate; IS, ischaemic stroke; ITT, Intention-to-treat; OT, On-treatment; SGLT2i, sodium-glucose co-transporter-2 inhibitor